Miltenyi, 170-076-139, MACS® GMP PepTivator® BKV LT

Background information
BKV is a ubiquitous polyomavirus. After primary infection BKV persists in a latent state. Virus reactivation might occur in immunodeficiency or during immunosuppression. The LT antigen is expressed early in the lytic cycle and is involved in virus replication.

Applications
Adoptive transfer of BKV LT-specific T cells may be an effective tool for the treatment of BKV-associated infections after stem cell transplantation or solid organ transplantation.1,2
In vitro stimulation of BKV LT-specific CD4+ and CD8+ T cells with MACS GMP PepTivator BKV LT causes the production of the effector cytokine IFN-γ. The secretion of IFN-γ then permits the enrichment of BKV LT-specific effector/memory T cells using the CliniMACS® Cytokine Capture System (IFN-γ).3

Quality statement
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

Disclaimer
MACS GMP Products are for ex vivo cell processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.

Overview
MACS GMP PepTivator BKV LT is a peptide pool that consists mainly of 15-mer peptides with 11 amino acids overlap. It has been developed for efficient in vitro stimulation and subsequent isolation of BKV LT-specific CD4+ and CD8+ T cells.